List of Bulk Drug Substances for Compounding Office Stock Drugs for Use in Nonfood-Producing Animals or Antidotes for Food-Producing Animals; Request for Nominations

Duane Blanton, DVM, representing Wallace Animal Hospital, opposes the FDA's decision to add ponazuril to the list of drugs that cannot be sold for bulk "in clinic" use. He argues that the restriction is harmful because it delays life-saving treatment for weak small animals and that the drug is currently unavailable in a safe form for small animal use.

A veterinary professional (implied by the context of "veterinary hospitals" and "available to us") is requesting that the FDA allow maropitant suspension to be included in the list of bulk drug substances for compounding. They argue that the current lack of a commercial liquid form causes unnecessary suffering for pets that cannot take pills, as waiting for compounded medication takes too long.

An emergency veterinarian's office is requesting the inclusion of sucralfate suspension on the list of bulk drug substances for compounding. They argue that the drug is essential for treating vomiting in pets and that commercially available tablets are too large for small animals to take effectively.

Dr. Mark A. Meier of Hays Veterinary Hospital argues that the current FDA guidance preventing the stocking of compounded pimobendan in offices has led to patient deaths due to medication delays. He requests that the FDA allow pimobendan to be compounded for office use to ensure small dogs with heart disease have immediate access to necessary medication.

A veterinarian (implied by the professional context and specific knowledge of medication sizes) opposes the proposed regulation, arguing that it removes essential bulk medications from veterinary offices. The commenter contends that the change will hinder patient care, particularly for small animals requiring specific dosages, and suggests the move favors compounding pharmacies over veterinary practice.

A veterinarian argues that Metronidazole should remain on the list of office stock drugs for compounding. They state that having small tablets available for immediate use is crucial for treating feline GI issues, as standard tablets are too large and waiting for compounded medications causes delays in care.

A veterinary professional argues that the current list of bulk drug substances for compounding is too restrictive and fails to meet the needs of many patients. They advocate for expanding the list to include more drugs and dosage forms to ensure timely and accurate treatment for animals, particularly those who cannot tolerate commercial products.